江苏吉贝尔药业股份有限公司独立董事 关于第三届董事会第十八次会议相关事项的 独立意见 根据《上市公司独立董事管理办法》《上市公司独立董事规则》《上海证券交 易所科创板股票上市规则》《江苏吉贝尔药业股份有限公司章程》（以下简称"《公 司章程》"）等相关要求，作为江苏吉贝尔药业股份有限公司（以下简称"公司"） 的独立董事，我们本着认真负责、实事求是的态度，对公司第三届董事会第十八 次会议相关事项进行了认真的了解和查验并发表如下独立意见： 一、《公司 2023 年半年度募集资金存放与实际使用情况的专项报告》的 独立意见 我们认为：公司本次对 2021 年限制性股票激励计划限制性股票授予价 格的调整符合《上市公司股权激励管理办法》及公司《激励计划》中关于授 予价格调整的规定，本次调整事项在公司 2021 年第一次临时股东大会授权 董事会决策的事项范围内，且履行了必要的审批程序，本次授予价格调整合 法、有效，表决程序符合《中华人民共和国公司法》、《中华人民共和国证 券法》等有关法律、法规和《公司章程》的有关规定。我们同意公司本次对 2021 年限制性股票激励计划限制性股票授予价格进行调整，并同意本激励计 划第二个归属期 ...

独立董事候选人声明与承诺 本人杨国祥,已充分了解并同意由提名人江苏吉贝尔药业股份有 限公司董事会提名为江苏吉贝尔药业股份有限公司第四届董事会独 立董事候选人。本人公开声明，本人具备独立董事任职资格，保证不 存在任何影响本人担任江苏吉贝尔药业股份有限公司独立董事独立 性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有五年以上法律、经济会计、财 务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： (一)《中华人民共和国公司法》等关于董事任职资格的规定； (二)《中华人民共和国公务员法》关于公务员兼任职务的规定 (如适用); （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用） （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题的意见》的相关规定（如 ...

(以下无正文) (本页无正文,为《江苏吉贝尔药业股份有限公司监事会关于〈公司 2021 年限 制性股票激励计划第二个归属期激励对象归属名单>的核查意见》签署页) 监事签名: 王 李腊梅 江苏吉贝尔药业股份有限公司 监事会关于《公司 2021年限制性股票激励计划第二 个归属期激励对象归属名单》的核查意见 江苏吉贝尔药业股份有限公司〈以下简称"公司"》监事会根据《中华人民 共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下 简称"《证券法》")、《上市公司股权激励管理办法》(以下简称"《管理办 法》")、《上海证券交易所科创板股票上市规则》(以下简称"《上市规则》") 和《江苏吉贝尔药业股份有限公司章程》(以下简称"《公司章程》"等有关规 定,对《公司 2021年限制性股票激励计划第二个归属期激励对象归属名单》进 行审核,发表核查意见如下: 本次拟归属的 72 名激励对象符合《公司法》《证券法》等法律、法规和规 范性文件以及《公司章程》的有关规定,符合《管理办法》《上市规则》等法律、 法规和规范性文件规定的激励对象条件,符合公司 2021 年限制性股票激励计划 〈以下简称"本激励计划")规定 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2023-025 江苏吉贝尔药业股份有限公司 第三届董事会第十八次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第三届董事会第十八次 会议（以下简称"会议"）于 2023 年 8 月 18 日以书面方式发出通知，于 2023 年 8 月 29 日在公司会议室召开。会议应参加表决董事 7 名，实际参加表决董事 7 名，公司监事及高级管理人员列席了会议。本次会议符合《中华人民共和国公 司法》（以下简称"《公司法》"）及《江苏吉贝尔药业股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，会议合法有效。 二、董事会会议审议情况 表决情况：7 票同意、0 票反对和 0 票弃权。 表决结果：通过。 1 （二）审议通过《公司 2023 年半年度募集资金存放与实际使用情况的专项 报告》 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》《上海证券交易所 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2023-029 江苏吉贝尔药业股份有限公司 关于 2021 年限制性股票激励计划第二个归属期归属 条件成就的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、股权激励计划批准及实施情况 （一）本次股权激励计划方案及履行的程序 1、本次股权激励计划主要内容 （1）股权激励计划名称：江苏吉贝尔药业股份有限公司 2021 年限制性股票 激励计划（以下简称"本激励计划"） （2）股权激励方式：第二类限制性股票 （6）授予价格（调整后）：11.34 元/股。2023 年 8 月 29 日，公司召开第三 届董事会第十八次会议、第三届监事会第十六次会议，审议通过了《关于调整 2021 年限制性股票激励计划限制性股票授予价格的议案》，同意公司董事会根据 公司《江苏吉贝尔药业股份有限公司 2021 年限制性股票激励计划（草案）》（以 下简称"《激励计划》"）的有关规定，对本激励计划限制性股票授予价格进行调 1 限制性股票拟归属数量：2,142,376 股 归属股票来 ...

独立董事提名人声明与承诺 提名人江苏吉贝尔药业股份有限公司董事会, 现提名何娣为江苏 吉贝尔药业股份有限公司第四届董事会独立董事候选人 , 并已充分了 解被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重 大失信等不良记录等情况。被提名人已书面同意出任江苏吉贝尔药业 股份有限公司第四届董事会独立董事候选人 (参见该独立董事候选人 声明）。提名人认为，被提名人具备独立董事任职资格，与江苏吉贝 尔药业股份有限公司之间不存在任何影响其独立性的关系，具体声明 并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有五年以上法律、经济、会计、 财务、管理等履行独立董事职责所必需的工作经验。 （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用） （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题的意见》的相关规定（如适用)； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐 倡廉建设的意见》的相关规定（如适用） （七）中国人民银行《股份制商 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2023-034 江苏吉贝尔药业股份有限公司 关于参加 2023 年半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 9 月 7 日（星期四）下午 13:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （一）会议线上交流时间：2023 年 9 月 7 日（星期四）下午 13:00-15:00 （二）会议召开方式：视频和线上文字互动 （三）视频和网路文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 6 日（星期三）16:00 前通过邮件、电话等形式将 需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关 注的问题进行回答。 江苏吉贝尔药业股份有限公司（ ...

证券代码：688566 证券简称：吉贝尔 公告编号：2023-015 江苏吉贝尔药业股份有限公司 关于参加 2022 年度集体业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 6 月 14 日（星期三）下午 14:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 投资者可于 2023 年 6 月 13 日（星期二）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍 关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日 在上海证券交易所网站（www.sse.com.cn）发布《公司 2022 年年度报告》，为便 于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况、发展理念， 公司参与了由上海证券交易所主办的 2022 年度 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥165,341,239.75, representing a year-on-year increase of 19.10%[5] - The net profit attributable to shareholders for the same period was ¥38,010,611.11, reflecting a growth of 32.98% compared to the previous year[5] - Basic and diluted earnings per share both stood at ¥0.20, up by 33.33% from the previous year[5] - Total revenue for Q1 2023 reached ¥165,341,239.75, an increase of 19.06% compared to ¥138,822,101.80 in Q1 2022[20] - Operating profit for Q1 2023 was ¥40,125,232.79, up from ¥32,539,476.75 in Q1 2022, reflecting a growth of 23.88%[20] - Net profit for Q1 2023 was ¥37,907,684.96, compared to ¥28,472,006.74 in Q1 2022, representing a year-over-year increase of 33.24%[21] - Earnings per share for Q1 2023 were ¥0.20, up from ¥0.15 in Q1 2022, indicating a growth of 33.33%[21] - Cash flow from operating activities for Q1 2023 was ¥102,656,045.82, significantly higher than ¥17,129,889.13 in Q1 2022[22] - Total operating costs for Q1 2023 were ¥122,667,342.99, an increase of 15.59% from ¥106,108,841.42 in Q1 2022[20] - The company reported a decrease in income tax expenses to ¥2,055,745.20 in Q1 2023 from ¥4,044,601.59 in Q1 2022, a reduction of 49.32%[21] Cash Flow and Assets - The net cash flow from operating activities surged to ¥102,656,045.82, marking an impressive increase of 499.28% year-on-year[5] - Cash inflow from operating activities totaled ¥238,889,526.09 in Q1 2023, compared to ¥144,454,113.86 in Q1 2022, marking an increase of 65.41%[22] - The total assets at the end of the reporting period were ¥1,964,513,238.45, showing no significant change from the previous year[6] - As of March 31, 2023, the total current assets amounted to RMB 1,111,541,817.52, a decrease from RMB 1,256,773,525.38 at the end of 2022, reflecting a decline of approximately 11.5%[15] - The total non-current assets increased to RMB 852,971,420.93 from RMB 707,801,585.52, representing a growth of about 20.5%[16] - The total liabilities decreased to RMB 226,867,592.85 from RMB 270,244,965.69, indicating a reduction of approximately 16.1%[16] - The cash and cash equivalents were reported at RMB 722,824,564.93, down from RMB 903,903,294.77, which is a decline of around 20%[15] - The ending balance of cash and cash equivalents as of Q1 2023 was $722.49 million, up from $506.57 million in the same period last year[23] Shareholder Information - The equity attributable to shareholders increased by 2.57% to ¥1,731,848,212.37 compared to the end of the previous year[6] - The company reported a total of 7,544 common shareholders at the end of the reporting period[10] - The total equity remained stable at RMB 1,737,645,645.60, with no significant changes reported[16] Research and Development - Research and development expenses totaled ¥8,534,363.18, accounting for 5.16% of operating revenue, which is an increase of 0.10 percentage points[6] - Research and development expenses for Q1 2023 amounted to ¥8,534,363.18, up from ¥7,028,935.99 in Q1 2022, reflecting a growth of 21.41%[20] Non-Recurring Items and Other Information - Non-recurring gains and losses amounted to ¥280,851.05, after accounting for tax effects[7] - The weighted average return on net assets was 2.22%, an increase of 0.46 percentage points[5] - The company did not participate in any financing or margin trading activities during the reporting period[13] - There were no new product launches or technological advancements mentioned in the report[14] - The company has not disclosed any plans for market expansion or mergers and acquisitions in the near future[14] - The net cash flow from investing activities for Q1 2023 was -$280.67 million, compared to -$525.26 million in Q1 2022, indicating an improvement[23] - The total cash outflow from financing activities was $865,166.39, with a net cash flow from financing activities of $295,018.61[23] - The net increase in cash and cash equivalents for Q1 2023 was -$177.72 million, compared to -$508.13 million in Q1 2022, showing a reduction in cash burn[23] - The company has implemented new accounting standards starting in 2023, which may affect financial reporting[23]

Financial Performance - The company's operating revenue for 2022 was ¥654,730,646.35, representing a year-on-year increase of 28.46% compared to ¥509,693,982.77 in 2021 [25]. - The net profit attributable to shareholders of the listed company was ¥154,667,820.31, up 34.61% from ¥114,901,343.14 in the previous year [25]. - The basic earnings per share for 2022 was ¥0.83, reflecting a 36.07% increase from ¥0.61 in 2021 [26]. - The net cash flow from operating activities was ¥150,724,074.86, showing a slight increase of 0.11% compared to ¥150,556,993.47 in 2021 [25]. - The total assets at the end of 2022 were ¥1,964,575,110.90, an increase of 8.02% from ¥1,818,686,866.85 at the end of 2021 [25]. - The company's net assets attributable to shareholders at the end of 2022 were ¥1,688,429,785.82, a 5.40% increase from ¥1,601,985,101.69 at the end of 2021 [25]. - The company's cash flow from operating activities was approximately ¥150.72 million, showing a slight increase of 0.11% compared to the previous year [139]. - The company reported a significant increase in production volume for Nifedipine Tablets, up 112.53% year-over-year, while sales volume increased by 25.46% [144]. Research and Development - The company's R&D investment as a percentage of operating revenue was 8.43%, up from 5.75% in the previous year, indicating a focus on innovation [27]. - The total R&D investment for the year reached ¥55,180,366.07, an increase of 88.44% compared to ¥29,282,498.21 in the previous year, with R&D expenses accounting for 8.43% of total revenue [99][100]. - The company is developing a new antidepressant drug JJH201501, which has shown significant antidepressant effects and improved learning and memory in Phase I clinical trials, currently progressing to Phase IIb trials [58]. - The anti-tumor drug JJH201601 has demonstrated superior tumor suppression effects compared to imported docetaxel injection in various models, with lower side effects, and is moving forward with Phase I clinical trials [59]. - The company has established a comprehensive drug development system, focusing on patient needs and clinical value, supported by a professional R&D team and various research departments [65]. - The company is actively pursuing clinical trials for multiple new drugs, including JJH201501 and JJH201601, indicating a robust pipeline for future growth [101]. - The company has established a research and development platform focusing on compound formulations, deuterated drugs, and liposome drug technologies [169]. - Major R&D projects included JJH201501 and JJH201601, with respective investments of CNY 1,765.12 million and CNY 1,846.51 million, reflecting year-on-year increases of 165.82% and 99.29% [182]. Market and Product Development - The company attributed its strong performance to enhanced product channel construction and market development efforts, leading to rapid sales growth [27]. - The company's main products include tablets, capsules, and eye drops, with key products like Licorice Tablets and Nifedipine Tablets being recognized as essential medications in their respective categories [47][49]. - Licorice Tablets have been included in the National Basic Medical Insurance Directory (2022) and are widely used in thousands of hospitals across China, demonstrating a strong market presence [48]. - The company’s main product, Likujun tablets, is a leading drug in the leukocyte-boosting category, widely used in various medical fields, ensuring a strong market share [77]. - The company is actively expanding its marketing system and has established dedicated departments to enhance academic support and business operations [70]. - The company has established a comprehensive marketing network across China, enhancing product promotion through expert networks and academic outreach, effectively covering major target markets [117]. Governance and Compliance - The company has received a standard unqualified audit report from Xinyong Zhonghe Accounting Firm [5]. - The company has confirmed that all board members were present at the board meeting [5]. - The board of directors consists of 7 members, including 3 independent directors, ensuring effective governance and compliance with legal requirements [199]. - The company has established a supervisory board with three members, including a representative from employees, to protect shareholder rights and interests [200]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [10]. - The company has not experienced any violations of decision-making procedures regarding external guarantees [10]. - The company has not reported any special arrangements in corporate governance [10]. Risks and Challenges - The company is currently facing risks related to new drug development, including potential delays in obtaining clinical trial approvals for its innovative drugs [124]. - The company’s main product, Li Ke Jun, has multiple layers of technical barriers, but faces risks from potential imitation or substitution by other pharmaceutical companies [123]. - The company relies heavily on the revenue from its main product, Likujun tablets, which poses a risk if faced with increased competition or changes in the operating environment [127]. - The company faces risks related to the approval of new drug applications, which may not meet expectations due to long development cycles and regulatory uncertainties [127]. - The company is exposed to credit risk, with accounts receivable and notes receivable totaling approximately ¥216.21 million, accounting for 17.2% of current assets [132]. - The company is at risk of price reductions due to national drug procurement policies, which could impact revenue and profitability if its main products are included in procurement lists [135]. - The company is actively monitoring macroeconomic risks and is prepared to implement measures to mitigate potential impacts on its business [136]. Talent and Human Resources - A total of 263 talents were recruited during the reporting period, including 102 with a bachelor's degree or higher, supporting the company's high-quality development [45]. - The R&D personnel count is 101, accounting for 9.94% of the total workforce, with an average salary of CNY 175,756.98 [112]. - The company has conducted 127 training sessions throughout the year, with over 1,400 participants, to foster talent development and retention [45]. - The company is committed to talent acquisition and development, establishing a robust human resources management system to foster innovation and enhance team capabilities [196]. Production and Operations - The company has completed the construction of over 30,000 square meters of production facilities, including a comprehensive formulation workshop and two specialized workshops, enhancing its competitive advantage in the industry [42]. - The company maintains a production model based on planned production, ensuring adequate inventory to meet market demand while adhering to GMP certification standards [70]. - The procurement department manages the supply of raw materials and packaging, ensuring quality through supplier audits and maintaining safety stock levels [66]. - The company has implemented internal control systems for procurement and supplier evaluation, ensuring compliance and effective execution during the reporting period [68]. - The company is advancing the construction of production and R&D centers to enhance capacity and support clinical research for its anti-tumor drug JJH201601 [195].